Anxiety Disorders and Depression Treatment Market Size and Forecasts (2021 - 2031), Global and Regional Share, Trends, and Growth Opportunity Analysis
MARKET INTRODUCTION
As per the Anxiety and Depression of America, approximately 322 million people are living with depression worldwide. Anxiety disorders are the most common mental disorders. However, they are treatable, and a number of treatments are available to help patients. Anxiety and depression are different conditions but mostly coexist. Nearly 50% of the population diagnosed with depression is also diagnosed with anxiety. These disorders cause people to avoid situations and trigger panic attacks.
MARKET DYNAMICS
The anxiety disorders and depression treatment market is anticipated to grow in the forecast period owing to the increasing prevalence of anxiety disorders and depression globally. Currently, developed countries are grappling with mental illnesses hugely. For instance, in the U.S., around 10 million people suffer from mental illness every year. This can be attributed to the increasing anxious millennial population in the region. Apart from this, increasing awareness and the growing contribution of government organizations to ease disease burden are further boosting the growth of the market. Some of the prominent organizations working in this space are the Hope for Depression, the National Alliance on Mental Illness, and the American Psychiatric Association, among others. In addition, an increase in research and development activities are opening new growth avenues for the market.
- For instance, in 2021, Johnson & Johnson received approval for its ketamine-based depression treatment
- Another notable advancement was the approval of first postpartum depression drug brexanolone by Sage Therapeutics in March 2019
MARKET SCOPE
The "Global Anxiety Disorders and Depression Treatment Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of anxiety disorders and depression treatment market with detailed market segmentation by drug type, therapies, devices, application, end user and geography. The global anxiety disorders and depression treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading anxiety disorders and depression treatment market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global anxiety disorders and depression treatment market is segmented on the basis of drug class, therapies, devices, application and end users. Based on drug class, the market is segmented as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), antidepressant drugs, atypical antipsychotics, benzodiazepines, beta-blockers. Based on therapies, the market is segmented as electroconvulsive therapy (ECT), psychotherapy, deep brain stimulation, cognitive behavior therapy (CBT), cranial electrotherapy stimulation (CES), trans cranial magnetic stimulation (TMS). Based on devices, the market is segmented as cranial electrotherapy stimulator and fisher-wallace stimulator market. Based on application, the market is segmented into phobia, obsessive compulsive disorder (OCD), post-traumatic stress disorder, major depressive disorder and others. Based on end user, the market is segmented into hospitals, mental healthcare centers and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global anxiety disorders and depression treatment market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The anxiety disorders and depression treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting anxiety disorders and depression treatment market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the anxiety disorders and depression treatment market in these regions.
By Drug Class [Selective Serotonin Reuptake Inhibitors
By Therapies [Electroconvulsive Therapy
By Devices
By Application
MARKET PLAYERS
The report covers key developments in the anxiety disorders and depression treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from anxiety disorders and depression treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for anxiety disorders and depression treatment market in the global market. Below mentioned is the list of few companies engaged in the anxiety disorders and depression treatment market.
The report also includes the profiles of key anxiety disorders and depression treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Sumitomo Dainippon Pharma Co.
- Sage Therapeutics
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Abbott
- Sanofi
- H. Lundbeck A/S
- Johnson & Johnson
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
As per the Anxiety and Depression of America, approximately 322 million people are living with depression worldwide. Anxiety disorders are the most common mental disorders. However, they are treatable, and a number of treatments are available to help patients. Anxiety and depression are different conditions but mostly coexist. Nearly 50% of the population diagnosed with depression is also diagnosed with anxiety. These disorders cause people to avoid situations and trigger panic attacks.
MARKET DYNAMICS
The anxiety disorders and depression treatment market is anticipated to grow in the forecast period owing to the increasing prevalence of anxiety disorders and depression globally. Currently, developed countries are grappling with mental illnesses hugely. For instance, in the U.S., around 10 million people suffer from mental illness every year. This can be attributed to the increasing anxious millennial population in the region. Apart from this, increasing awareness and the growing contribution of government organizations to ease disease burden are further boosting the growth of the market. Some of the prominent organizations working in this space are the Hope for Depression, the National Alliance on Mental Illness, and the American Psychiatric Association, among others. In addition, an increase in research and development activities are opening new growth avenues for the market.
- For instance, in 2021, Johnson & Johnson received approval for its ketamine-based depression treatment
- Another notable advancement was the approval of first postpartum depression drug brexanolone by Sage Therapeutics in March 2019
MARKET SCOPE
The "Global Anxiety Disorders and Depression Treatment Market Analysis to 2031" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of anxiety disorders and depression treatment market with detailed market segmentation by drug type, therapies, devices, application, end user and geography. The global anxiety disorders and depression treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading anxiety disorders and depression treatment market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global anxiety disorders and depression treatment market is segmented on the basis of drug class, therapies, devices, application and end users. Based on drug class, the market is segmented as selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), antidepressant drugs, atypical antipsychotics, benzodiazepines, beta-blockers. Based on therapies, the market is segmented as electroconvulsive therapy (ECT), psychotherapy, deep brain stimulation, cognitive behavior therapy (CBT), cranial electrotherapy stimulation (CES), trans cranial magnetic stimulation (TMS). Based on devices, the market is segmented as cranial electrotherapy stimulator and fisher-wallace stimulator market. Based on application, the market is segmented into phobia, obsessive compulsive disorder (OCD), post-traumatic stress disorder, major depressive disorder and others. Based on end user, the market is segmented into hospitals, mental healthcare centers and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global anxiety disorders and depression treatment market based on various segments. It also provides market size and forecast estimates from year 2021 to 2031 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The anxiety disorders and depression treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting anxiety disorders and depression treatment market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the anxiety disorders and depression treatment market in these regions.
Anxiety Disorders and Depression Treatment Market Report Analysis
Anxiety Disorders and Depression Treatment Market
-
CAGR (2023 - 2031)XX% -
Market Size 2023
US$ XX Million -
Market Size 2031
US$ XX Million
Report Coverage
- Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Key future trends
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Industry landscape and competition analysis & recent developments
- Detailed company profiles
- Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Key Players
- Sumitomo Dainippon Pharma Co.
- Sage Therapeutics
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Abbott
- Sanofi
- H. Lundbeck A/S
Regional Overview
- North America
- Europe
- Asia-Pacific
- South and Central America
- Middle East and Africa
Market Segmentation
By Drug Class [Selective Serotonin Reuptake Inhibitors
- SSRIs
- Tricyclic Antidepressants
By Therapies [Electroconvulsive Therapy
- ECT
- Psychotherapy
- Deep Brain Stimulation
- Cognitive Behavior Therapy
By Devices
- Cranial Electrotherapy Stimulator
- fisher-wallace stimulator
By Application
- Phobia
- Obsessive Compulsive Disorder
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
The report covers key developments in the anxiety disorders and depression treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from anxiety disorders and depression treatment market are anticipated to lucrative growth opportunities in the future with the rising demand for anxiety disorders and depression treatment market in the global market. Below mentioned is the list of few companies engaged in the anxiety disorders and depression treatment market.
The report also includes the profiles of key anxiety disorders and depression treatment market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Sumitomo Dainippon Pharma Co.
- Sage Therapeutics
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
- Eli Lilly and Company
- Abbott
- Sanofi
- H. Lundbeck A/S
- Johnson & Johnson
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Anxiety Disorders and Depression Treatment Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ XX Million |
| Market Size by 2031 | US$ XX Million |
| Global CAGR (2023 - 2031) | XX% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Drug Class [Selective Serotonin Reuptake Inhibitors
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
|
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
The List of Companies
1. Sumitomo Dainippon Pharma Co.
2. Sage Therapeutics
3. GlaxoSmithKline plc
4. F. Hoffmann-La Roche Ltd
5. Eli Lilly and Company
6. Abbott
7. Sanofi
8. H. Lundbeck A/S
1. Sumitomo Dainippon Pharma Co.
2. Sage Therapeutics
3. GlaxoSmithKline plc
4. F. Hoffmann-La Roche Ltd
5. Eli Lilly and Company
6. Abbott
7. Sanofi
8. H. Lundbeck A/S
Get Free Sample For